Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. (Q46708418)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

S. Vincent Rajkumar

series ordinal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

8

M R Litzow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

9

M A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

4

M Q Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

6

F K Buadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2

D Dingli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

S K Kumar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

S R Hayman

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

10 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1013-1019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18332915%20AND%20SRC:MED&resulttype=core&format=json

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.24

7 January 2021